Published in Antimicrob Agents Chemother on April 20, 2015
Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide After Renal Transplant | NCT04530630
The promise and pitfalls of long-acting injectable agents for HIV prevention. Curr Opin HIV AIDS (2016) 0.90
Application of electrospun fibers for female reproductive health. Drug Deliv Transl Res (2017) 0.84
Long acting systemic HIV pre-exposure prophylaxis: an examination of the field. Drug Deliv Transl Res (2017) 0.82
Preferences for Long-Acting Pre-exposure Prophylaxis (PrEP), Daily Oral PrEP, or Condoms for HIV Prevention Among U.S. Men Who Have Sex with Men. AIDS Behav (2016) 0.81
Comparison of Dapivirine Vaginal Gel and Film Formulation Pharmacokinetics and Pharmacodynamics (FAME 02B). AIDS Res Hum Retroviruses (2016) 0.77
Creation of a Long-Acting Nanoformulated 2',3'-Dideoxy-3'-Thiacytidine. J Acquir Immune Defic Syndr (2016) 0.76
A Tunable, Biodegradable, Thin-Film Polymer Device as a Long-Acting Implant Delivering Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis. Pharm Res (2016) 0.76
The preexposure prophylaxis revolution: from clinical trials to routine practice: implementation view from the USA. Curr Opin HIV AIDS (2016) 0.75
A Convenient Truth: Cost of Medications Need Not Be a Barrier to Hepatitis B Treatment. Glob Health Sci Pract (2016) 0.75
Combination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model. Antimicrob Agents Chemother (2016) 0.75
A Review of HIV Pre-Exposure Prophylaxis: The Female Perspective. Infect Dis Ther (2017) 0.75
Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues. J Antimicrob Chemother (2017) 0.75
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med (2012) 20.03
Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med (2011) 6.79
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med (2012) 6.29
The origin of allometric scaling laws in biology from genomes to ecosystems: towards a quantitative unifying theory of biological structure and organization. J Exp Biol (2005) 3.30
Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm (2009) 2.79
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother (2010) 2.41
MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One (2013) 2.39
Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here? Lancet (2013) 2.31
To scale or not to scale: the principles of dose extrapolation. Br J Pharmacol (2009) 2.07
Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav (2013) 2.03
Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue. AIDS Res Hum Retroviruses (2013) 1.76
Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV AIDS (2013) 1.73
Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother (2005) 1.63
The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends Pharmacol Sci (2009) 1.62
Implantable, polymeric systems for modulated drug delivery. Adv Drug Deliv Rev (2002) 1.42
Intravitreal sustained-release ganciclovir. Arch Ophthalmol (1992) 1.39
State of the science of adherence in pre-exposure prophylaxis and microbicide trials. J Acquir Immune Defic Syndr (2012) 1.37
Exploring concentration response in HIV pre-exposure prophylaxis to optimize clinical care and trial design. Cell (2013) 1.25
Cell volumes of normal and malignant mononuclear cells. J Clin Pathol (1981) 1.23
A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis. Clin Pharmacol Ther (2014) 1.20
An intravaginal ring for the simultaneous delivery of multiple drugs. J Pharm Sci (2012) 1.17
Is resistance futile? Curr Drug Targets Infect Disord (2003) 1.14
Effects of heat treatment on the permeability of polyvinyl alcohol films to a hydrophilic solute. J Pharm Sci (1987) 1.13
Long-acting HIV drugs advanced to overcome adherence challenge. Nat Med (2014) 1.08
Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. Nanomedicine (Lond) (2013) 1.03
Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection. Int J Clin Pharm (2013) 1.02
Dosage frequency and drug-compliance behaviour--a comparative study on compliance with a medication to be taken twice or four times daily. Eur J Clin Pharmacol (1991) 1.00
Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340. Mol Pharm (2012) 0.98
Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. J Antimicrob Chemother (2014) 0.94
An intravaginal ring for the sustained delivery of antibodies. J Pharm Sci (2014) 0.90
An overview of antiretroviral pre-exposure prophylaxis of HIV infection. Am J Reprod Immunol (2014) 0.87
Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention. Clin Pharmacokinet (2014) 0.86
Linking the population pharmacokinetics of tenofovir and its metabolites with its cellular uptake and metabolism. CPT Pharmacometrics Syst Pharmacol (2014) 0.85
Vaginal microbicides and their delivery platforms. Expert Opin Drug Deliv (2014) 0.81
Correlation of in vitro-in vivo release rates for sustained release nevirapine implants in rats. J Control Release (2005) 0.79
Pharmacokinetics of injectable, long-acting nevirapine for HIV prophylaxis in breastfeeding infants. Antimicrob Agents Chemother (2014) 0.78
MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel. Clin Infect Dis (2016) 0.78
Pharmacokinetics of injectable, long-acting nevirapine for HIV prophylaxis in breastfeeding infants. Antimicrob Agents Chemother (2014) 0.78
Pharmacokinetics and Preliminary Safety of Pod-Intravaginal Rings Delivering the Monoclonal Antibody VRC01-N for HIV Prophylaxis in a Macaque Model. Antimicrob Agents Chemother (2017) 0.76
Combination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model. Antimicrob Agents Chemother (2016) 0.75